The ambitious Japanese drugmaker is closing in on a $64 bln takeover of Irish counterpart Shire. But the sheer size of the deal poses a problem, as Jeff Goldfarb tells Quentin Webb. That means a lot of stock, a fluctuating offer price, and an opening for rival bidders.
from Reuters Video: Breakingviews https://ift.tt/2JzKSVf
via
IFTTT
No comments:
Post a Comment